Aurobindo Pharma demonstrates good financial performance and growth. The company has shown consistent sales growth over the years. The compounded sales growth shows a positive trend with TTM at 12%. The compounded profit growth, although showing -1% over the last 3 years, has a TTM growth of 54%. This indicates recent improvements in profitability. However, sales growth was higher between 2014 and 2019 compared to 2020 onwards, indicating some slowdown in growth rate over time.

Aurobindo Pharma's capital efficiency and returns show a mixed trend. The Return on Capital Employed (ROCE) has generally declined over the past few years, with the current ROCE at 11.56%. Similarly, the Return on Equity (ROE) has also seen a decrease, with the current ROE at 10.06%. While the company has maintained decent asset turnover, the declining ROCE indicates that capital is not being utilized as efficiently as it was in the past.

Aurobindo Pharma's financial health and prudence indicate some concerns. The company's borrowings have increased over the years, with total borrowings rising from ₹5,286 Cr in Mar 2023 to ₹8,427 Cr in Sep 2024. The Debt/Equity ratio also reflects this increasing leverage. The interest coverage ratio, while still adequate, has shown some fluctuations. The dividend payout has been consistent, but relatively low.

Aurobindo Pharma has a stable shareholding and ownership structure. The promoter holding has been consistently high, around 51.8% over the past few years, indicating strong confidence and alignment with shareholders. The FII holding has decreased from 21.37% in Dec 2021 to 16.59% in Sep 2024, while the DII holding has increased from 16.49% in Dec 2021 to 25.14% in Sep 2024. This shift indicates increasing domestic institutional interest in the company.

Aurobindo Pharma's interest payments have risen, which may affect profitability. It is essential to consider the foreign exchange risk to minimize any negative effects on the company's profits. The company's interest expenses have risen over time, which could lower profits.

The expenses of Aurobindo Pharma have risen over time. It is important to analyze any changes in regulatory compliance costs, as these could affect the company's financial results. The rise in expenses could put pressure on Aurobindo Pharma's profit margins.

The quarterly sales and profit figures for Aurobindo Pharma demonstrate some volatility, indicating potential risks in segment performance. YOY Sales Growth % and YOY Profit Growth % fluctuate, which could affect overall financial stability.

Aurobindo Pharma's other liabilities have been increasing, which might suggest possible contingent liabilities. Further analysis is needed to determine the effect of these liabilities on the company's financial stability. An increase in other liabilities could have an impact on the company's financial health.